Chapter 21: Histamine and Bradykinin Pharmacology — Module 4: Bradykinin Clinical Pharmacology — HAE Therapeutics, Neprilysin Inhibition, and Emerging Targets Core Concepts — Foundational Knowledge (22 questions)
1. A 34-year-old woman with hereditary angioedema (HAE) — a condition in which deficiency of the protein C1 inhibitor leads to uncontrolled generation of bradykinin, causing episodes of tissue swelling — presents to the emergency department with a rapidly progressing laryngeal attack. She is treated with icatibant. Which of the following best describes the pharmacological mechanism of icatibant?
A) Icatibant inhibits plasma kallikrein, the enzyme that generates bradykinin from its precursor protein, thereby preventing bradykinin formation at the source.
B) Icatibant is a competitive antagonist at the bradykinin B2 receptor, blocking the ability of bradykinin already present in tissues to produce its vascular permeability effects.
C) Icatibant inhibits the enzyme neprilysin, which is one of the principal pathways for bradykinin degradation, thereby reducing systemic bradykinin levels.
D) Icatibant is a recombinant form of C1 inhibitor that restores physiological control of the kallikrein-kinin system by replacing the deficient serpin.
E) Icatibant activates the bradykinin B1 receptor, which counteracts the vasodilatory effects of B2 receptor stimulation by producing vasoconstriction at affected tissue sites.
ANSWER: B
Rationale:
Icatibant (Firazyr) is a synthetic decapeptide that acts as a competitive antagonist at the bradykinin B2 receptor with high selectivity and no agonist properties. By occupying the B2 receptor, it prevents bradykinin — already generated and present in the affected tissues — from producing its downstream effects on vascular permeability, vasodilation, and pain. This mechanism makes icatibant effective regardless of how much bradykinin has already accumulated at the attack site.
Option A: Option A is incorrect because inhibiting plasma kallikrein (preventing bradykinin generation) describes the mechanism of ecallantide, not icatibant; icatibant acts downstream at the receptor level rather than at the biosynthetic step.
Option C: Option C is incorrect because neprilysin inhibition is the mechanism of sacubitril, which raises bradykinin levels by impairing one of its degradation pathways — the opposite of blocking bradykinin's action.
Option D: Option D is incorrect because recombinant C1 inhibitor replacement (e.g., Ruconest/conestat alfa) is a separate class of HAE treatment that addresses the upstream cause of uncontrolled kallikrein activation, not the receptor mechanism by which icatibant works.
Option E: Option E is incorrect because icatibant has minimal B1 receptor activity, is not a B1 agonist, and the premise that B1 activation counteracts B2 effects through vasoconstriction is pharmacologically inaccurate; both B1 and B2 receptors mediate vasodilatory and pro-permeability effects in HAE, and icatibant's therapeutic role is antagonism, not agonism.
2. A patient with confirmed hereditary angioedema is prescribed icatibant as rescue therapy for acute attacks. The prescribing clinician counsels the patient on the route of administration, dose, and the option for self-administration at home. Which of the following correctly describes the standard administration of icatibant for an acute HAE attack?
A) Icatibant is administered intravenously at a dose of 20 IU/kg by a healthcare provider in a clinical setting; self-administration is not permitted because of the risk of anaphylaxis.
B) Icatibant is given as three separate 10 mg subcutaneous injections at different sites during a single treatment session, with administration required in a healthcare setting.
C) Icatibant is taken orally at the first sign of an attack; its oral bioavailability allows it to reach therapeutic plasma concentrations within 30 minutes of ingestion.
D) Icatibant is administered subcutaneously as a single 30 mg injection and may be self-administered by a trained patient at home, making it suitable for community management of HAE attacks.
E) Icatibant is administered intramuscularly at a dose of 30 mg and requires observation for at least two hours in a clinical setting after injection because of the risk of delayed anaphylaxis.
ANSWER: D
Rationale:
Icatibant is administered subcutaneously at a dose of 30 mg as a single injection. A key clinical advantage is that patients can be trained to self-administer icatibant at home, which is particularly important in HAE because attacks frequently begin in community settings and time to treatment is a major determinant of attack severity and duration. The ability to self-inject at home sharply reduces the delay that would occur if every attack required travel to a healthcare facility.
Option A: Option A is incorrect because the dose of 20 IU/kg intravenously describes Berinert (plasma-derived C1 inhibitor concentrate), not icatibant; icatibant is subcutaneous and does not require IV access.
Option B: Option B is incorrect because three separate 10 mg subcutaneous injections at different sites during one session describes the administration of ecallantide (Kalbitor), not icatibant; additionally, ecallantide must be given in a healthcare setting because of anaphylaxis risk, which is a distinction that separates it from icatibant.
Option C: Option C is incorrect because icatibant is not orally bioavailable; as a peptide-based molecule, it is degraded by gastrointestinal proteases and must be delivered parenterally.
Option E: Option E is incorrect because icatibant is subcutaneous, not intramuscular, and the requirement for supervised clinical administration following injection applies to ecallantide (due to anaphylaxis risk), not to icatibant.
3. A 19-year-old male with HAE presents to the emergency department with a severe abdominal attack. The attending physician administers ecallantide (Kalbitor). Which of the following correctly identifies the pharmacological target of ecallantide and explains how targeting that step interrupts the HAE attack?
A) Ecallantide is a potent, selective inhibitor of plasma kallikrein — the serine protease that cleaves high-molecular-weight kininogen to generate bradykinin — thereby preventing new bradykinin formation before it can drive vascular permeability at the attack site.
B) Ecallantide is a competitive antagonist at the bradykinin B2 receptor, blocking the ability of circulating bradykinin to bind its receptor and trigger the downstream signaling cascade responsible for HAE-associated tissue edema.
C) Ecallantide inhibits factor XII (Hageman factor), the contact activation protein that initiates the kallikrein-kinin cascade when exposed to negatively charged surfaces, thereby preventing the entire downstream sequence from being triggered.
D) Ecallantide is a recombinant form of C1 inhibitor that replaces the deficient serpin in HAE types I and II, restoring physiological inhibition of both plasma kallikrein and complement pathway components.
E) Ecallantide inhibits neprilysin and ACE simultaneously, blocking the two principal enzymes responsible for bradykinin degradation and thereby reducing systemic bradykinin levels during an acute attack.
ANSWER: A
Rationale:
Ecallantide (Kalbitor) is a recombinant 60-amino-acid protein that acts as a potent, highly selective competitive inhibitor of plasma kallikrein, the serine protease that cleaves high-molecular-weight kininogen (HMWK) to generate bradykinin. By blocking kallikrein at this biosynthetic step, ecallantide prevents the formation of new bradykinin rather than blocking its action at the receptor level. This upstream mechanism distinguishes ecallantide from icatibant, which acts downstream at the B2 receptor.
Option B: Option B is incorrect because B2 receptor antagonism describes the mechanism of icatibant; ecallantide acts at the enzyme level (kallikrein) rather than at the receptor level, preventing bradykinin from being generated rather than blocking its signaling.
Option C: Option C is incorrect because factor XII inhibition describes the mechanism of garadacimab, an anti-factor XIIa monoclonal antibody in development; ecallantide acts one step downstream of factor XII, at kallikrein itself.
Option D: Option D is incorrect because recombinant C1 inhibitor replacement describes Ruconest (conestat alfa), which restores the deficient serpin; ecallantide is a kallikrein inhibitor that does not affect C1 inhibitor levels or complement pathway activity.
Option E: Option E is incorrect because simultaneous inhibition of neprilysin and ACE describes no currently approved drug for HAE; this framing conflates the bradykinin degradation enzymes (relevant to sacubitril pharmacology) with ecallantide's mechanism, which is entirely on the biosynthetic (generation) side of bradykinin pharmacology.
4. A pharmacist reviewing standing orders for an HAE clinic notes that ecallantide carries a specific safety requirement that distinguishes it from icatibant. Which of the following correctly identifies the primary safety concern with ecallantide and the clinical restriction it imposes?
A) Ecallantide carries a risk of severe hepatotoxicity with repeated use, requiring baseline and periodic liver function testing and restricting its use to patients without pre-existing liver disease.
B) Ecallantide is a potent teratogen in animal models and is absolutely contraindicated in women of reproductive age unless effective contraception is confirmed at the time of each administration.
C) Ecallantide carries a risk of anaphylaxis — occurring in approximately 3.9% of patients, likely due to anti-ecallantide antibody development or direct mast cell activation — and must therefore be administered in a healthcare setting equipped to manage anaphylaxis.
D) Ecallantide causes dose-dependent QT prolongation and must be withheld in patients with baseline QTc greater than 450 ms, requiring a screening ECG before each dose.
E) Ecallantide produces significant injection site reactions including tissue necrosis at the administration site, requiring rotation of sites and limiting the total number of lifetime doses a patient may receive.
ANSWER: C
Rationale:
Anaphylaxis is the primary safety concern with ecallantide, occurring in approximately 3.9% of patients in clinical trials. The mechanism is attributed to the development of anti-ecallantide antibodies in some recipients and to possible direct mast cell activation by the recombinant protein. Because anaphylaxis can be severe and life-threatening, ecallantide is required to be administered in a healthcare setting with personnel and equipment available to manage anaphylaxis — this is the key clinical distinction separating ecallantide from icatibant, which may be self-administered at home.
Option A: Option A is incorrect because hepatotoxicity is not a recognized safety concern for ecallantide; hepatotoxicity is associated with danazol, the attenuated androgen used in HAE prophylaxis, which requires periodic liver function monitoring.
Option B: Option B is incorrect because teratogenicity is not a labeled concern for ecallantide; this restriction applies to danazol, which is an androgenic steroid with well-documented teratogenicity and is absolutely contraindicated in pregnancy.
Option D: Option D is incorrect because QT prolongation is not a recognized adverse effect of ecallantide; this type of cardiac safety concern is associated with certain antiarrhythmic agents and some antihistamines, not with kallikrein inhibitors.
Option E: Option E is incorrect because while injection site reactions (erythema, bruising, irritation) do occur with ecallantide's three-injection administration regimen, tissue necrosis and lifetime dose limits are not characteristics of ecallantide; these features are not part of its prescribing restrictions.
5. A second-year medical student reviews the pathophysiology of hereditary angioedema before a pharmacology exam. She wants to understand why C1 inhibitor (C1-INH) concentrate replacement is a logical treatment strategy for HAE types I and II. Which of the following correctly identifies the role of C1-INH deficiency in HAE pathophysiology?
A) C1-INH deficiency causes excessive complement activation through the classical pathway, leading to deposition of complement fragments in submucosal tissues and triggering mast cell degranulation with histamine release as the primary mediator of tissue edema.
B) C1-INH deficiency impairs the degradation of bradykinin by removing one of the three principal bradykinin-clearing enzymes from plasma, causing bradykinin to accumulate to pathological concentrations during attack triggers.
C) C1-INH deficiency prevents the liver from synthesizing adequate amounts of high-molecular-weight kininogen (HMWK), the bradykinin precursor, reducing the substrate available for kallikrein and paradoxically triggering a compensatory overproduction of plasma kallikrein.
D) C1-INH deficiency causes loss of a bradykinin B2 receptor downregulating protein, leading to upregulation of B2 receptors at vascular endothelium and abnormally heightened sensitivity to normal physiological bradykinin concentrations.
E) C1-INH is a serine protease inhibitor (serpin) that normally restrains plasma kallikrein and factor XIIa; its deficiency in HAE types I and II removes this brake, allowing uncontrolled kallikrein-mediated cleavage of HMWK and excess bradykinin generation that drives vascular permeability and tissue edema.
ANSWER: E
Rationale:
C1 inhibitor is a serpin — a serine protease inhibitor — that physiologically restrains both plasma kallikrein and factor XIIa (the contact activation factor that initiates the kallikrein-kinin cascade). In HAE types I (reduced C1-INH quantity) and II (dysfunctional C1-INH), removal of this regulatory brake allows plasma kallikrein to cleave HMWK without restraint, generating excess bradykinin. The bradykinin then activates B2 receptors at vascular endothelium, producing the vasodilation and increased vascular permeability responsible for the subcutaneous and submucosal edema of HAE attacks. Replacing C1-INH with concentrate directly addresses this root deficit by restoring the missing inhibitor.
Option A: Option A is incorrect because while C1-INH does regulate the classical complement pathway, HAE edema is not histamine-mediated; HAE attacks do not respond to antihistamines or corticosteroids, which is a key clinical distinguishing feature from allergic angioedema.
Option B: Option B is incorrect because C1-INH does not function as a bradykinin-degrading enzyme; bradykinin is cleared by ACE (kininase II), carboxypeptidase N, and neprilysin, not by C1-INH; C1-INH acts on the biosynthetic (generation) side by inhibiting kallikrein.
Option C: Option C is incorrect because HMWK synthesis is a hepatic function independent of C1-INH; C1-INH deficiency does not impair HMWK production or trigger compensatory kallikrein overproduction through a substrate-reduction mechanism.
Option D: Option D is incorrect because C1-INH has no known role in regulating B2 receptor expression or downregulation; receptor upregulation is not the pathophysiological mechanism of HAE, and this option misrepresents both the receptor biology and C1-INH function.
6. An emergency physician treats a 28-year-old man with HAE type I who presents with a severe abdominal attack and decides to use Berinert, a plasma-derived C1 inhibitor (pdC1-INH) concentrate. Which of the following correctly states the FDA-approved dosing for Berinert in the treatment of an acute HAE attack?
A) Berinert is administered as a fixed dose of 1000 IU intravenously regardless of body weight, given over 10 minutes; this dose is also used for routine prophylaxis every 3 to 4 days.
B) Berinert is administered intravenously at a weight-based dose of 20 IU/kg, which delivers sufficient C1-INH to restore plasma levels into or above the normal range and typically produces onset of symptom relief within 30 to 60 minutes.
C) Berinert is administered subcutaneously at a dose of 60 IU/kg twice weekly as the approved dosing regimen for both acute attacks and long-term prophylaxis in adult patients with HAE.
D) Berinert is administered intravenously at a dose of 50 IU/kg to a maximum of 4200 IU; its short half-life of approximately 3 hours limits its use to acute attack treatment and makes it unsuitable for prophylaxis.
E) Berinert is administered as a single intramuscular dose of 30 mg at attack onset; repeat dosing at 6-hour intervals is permitted if symptoms recur, up to a maximum of three doses per attack episode.
ANSWER: B
Rationale:
Berinert (CSL Behring) is a plasma-derived C1 inhibitor concentrate approved for acute HAE attack treatment in adults and children at a weight-based dose of 20 IU/kg administered intravenously. This dose delivers sufficient functional C1-INH to restore plasma levels into or above the normal physiological range, reinstituting inhibitory control over plasma kallikrein and factor XIIa and halting ongoing bradykinin generation. The onset of clinical symptom relief in trials was median 30 to 60 minutes, reflecting the time needed for the infused C1-INH to redistribute into the tissue compartment where kallikrein is active.
Option A: Option A is incorrect because the fixed 1000 IU dose used every 3 to 4 days describes the prophylactic dosing of Cinryze, not the acute attack dosing of Berinert; Berinert's approved acute dose is weight-based at 20 IU/kg.
Option C: Option C is incorrect because subcutaneous dosing at 60 IU/kg twice weekly describes HAEGARDA (the subcutaneous formulation of plasma-derived C1-INH, also by CSL Behring), which is specifically approved for routine prophylaxis rather than acute attack treatment; Berinert is an intravenous formulation.
Option D: Option D is incorrect because the dose of 50 IU/kg to a maximum of 4200 IU and the short half-life of approximately 3 hours describes Ruconest (recombinant C1-INH, conestat alfa), which is produced in transgenic rabbit milk and is a distinct product from Berinert.
Option E: Option E is incorrect because 30 mg intramuscularly with repeat dosing at 6-hour intervals describes the administration of icatibant, not Berinert; C1-INH concentrates are not administered intramuscularly.
7. A 32-year-old woman with HAE type I has been having frequent attacks despite trigger avoidance. Her immunologist discusses initiating lanadelumab (Takhzyro) for long-term prophylaxis. Which of the following correctly describes the mechanism of lanadelumab and how it differs from C1 inhibitor concentrate prophylaxis?
A) Lanadelumab is a fully human IgG1 monoclonal antibody that binds and inhibits plasma kallikrein directly, preventing bradykinin generation from HMWK without restoring C1-INH levels or affecting complement pathway activity — distinguishing it mechanistically from C1-INH replacement, which normalizes the entire contact activation cascade.
B) Lanadelumab is a recombinant form of C1 inhibitor derived from transgenic rabbit milk that replaces the deficient serpin in HAE types I and II, restoring physiological inhibition of both plasma kallikrein and classical complement components.
C) Lanadelumab is a competitive antagonist at the bradykinin B2 receptor formulated for subcutaneous injection with an extended half-life achieved through PEGylation, allowing monthly dosing for prophylaxis rather than the per-attack dosing required with icatibant.
D) Lanadelumab is a small-molecule inhibitor of factor XII that prevents contact activation of the kallikrein-kinin cascade at its initiating step, producing a broader suppression of the contact system than C1-INH replacement, which acts downstream at kallikrein.
E) Lanadelumab inhibits both plasma kallikrein and tissue kallikrein isoforms simultaneously, providing prophylaxis against HAE attacks while also reducing the baseline inflammatory tone at mucosal surfaces by suppressing tissue kallikrein-mediated kinin generation in epithelial cells.
ANSWER: A
Rationale:
Lanadelumab (Takhzyro) is a fully human IgG1 kappa monoclonal antibody that binds directly to plasma kallikrein and inhibits its enzymatic activity, preventing the cleavage of HMWK and the consequent generation of bradykinin. Unlike C1-INH concentrates, which replace the missing serpin and thereby restore physiological inhibition of both kallikrein and complement components (C1s, C1r), lanadelumab does not affect C1-INH levels or complement pathway function — it is a pharmacological kallikrein inhibitor rather than a physiological replacement therapy. This distinction is clinically relevant because lanadelumab's mechanism is narrowly targeted at one enzyme (plasma kallikrein), whereas C1-INH replacement normalizes the broader contact activation and complement system.
Option B: Option B is incorrect because recombinant C1-INH derived from transgenic rabbit milk describes Ruconest (conestat alfa), not lanadelumab; lanadelumab is a monoclonal antibody, not a replacement serpin.
Option C: Option C is incorrect because B2 receptor antagonism with PEGylation for extended dosing describes no currently approved agent; icatibant is a B2 antagonist but is not PEGylated and is used per-attack, not as prophylaxis; lanadelumab acts on kallikrein, not on the receptor.
Option D: Option D is incorrect because factor XII inhibition describes garadacimab, an anti-factor XIIa antibody in clinical development; lanadelumab targets kallikrein, which is one step downstream of factor XII in the contact activation cascade.
Option E: Option E is incorrect because lanadelumab selectively inhibits plasma kallikrein and does not inhibit tissue kallikrein isoforms; plasma kallikrein and tissue kallikreins are distinct enzymes with different substrates and tissue distributions, and lanadelumab's selectivity for plasma kallikrein is a defining pharmacological property.
8. A resident preparing a grand rounds presentation reviews the pivotal clinical trial for lanadelumab in HAE prophylaxis. Which of the following correctly summarizes the key efficacy finding from the HELP trial (the phase III randomized controlled trial of lanadelumab)?
A) The HELP trial demonstrated that lanadelumab at 300 mg every 2 weeks reduced HAE attack frequency by approximately 50% compared with placebo, with 12% of patients achieving complete attack freedom over the treatment period.
B) The HELP trial showed that lanadelumab was non-inferior to plasma-derived C1 inhibitor concentrate (Cinryze) administered intravenously every 3 to 4 days for attack prevention, with equivalent rates of attack freedom and comparable injection site reactions.
C) The HELP trial demonstrated that lanadelumab at 300 mg every 4 weeks was superior to every-2-week dosing for HAE prophylaxis, establishing once-monthly administration as the standard dosing regimen for all patients initiating therapy.
D) The HELP trial demonstrated that lanadelumab at 300 mg every 2 weeks reduced HAE attack rate by approximately 87% compared with placebo, with 44% of patients achieving complete attack freedom during the treatment period — establishing it as a highly effective prophylactic agent.
E) The HELP trial showed that lanadelumab reduced laryngeal HAE attacks specifically by 95% compared with placebo but had no statistically significant effect on abdominal or cutaneous attack frequency, limiting its primary indication to prevention of airway-threatening attacks.
ANSWER: D
Rationale:
The HELP (Hereditary Angioedema Long-term Prophylaxis) trial was the pivotal phase III randomized controlled trial that established lanadelumab's efficacy. At the 300 mg every-2-week dose, lanadelumab reduced the HAE attack rate by approximately 87% compared with placebo, and 44% of patients in the every-2-week arm achieved complete attack freedom during the treatment period. These efficacy figures represent a substantial advance over prior prophylactic options and supported FDA approval of lanadelumab for HAE prophylaxis.
Option A: Option A is incorrect because the 50% attack frequency reduction and 12% complete attack freedom are substantially lower than the actual HELP trial results; the 87% attack rate reduction and 44% complete attack freedom are the correct figures, and underrepresenting the efficacy mischaracterizes the drug's clinical impact.
Option B: Option B is incorrect because the HELP trial was a placebo-controlled trial, not a head-to-head comparison with C1-INH concentrate; direct comparative trials between lanadelumab and Cinryze or other prophylactic agents have not been conducted in the same trial framework, and non-inferiority to Cinryze was not the trial design.
Option C: Option C is incorrect because the HELP trial tested every-2-week and every-4-week dosing, with every-2-week dosing generally showing numerically superior efficacy; the approved initial regimen is 300 mg every 2 weeks for the first 6 months, not once monthly, with potential extension to every 4 weeks only in patients who are well-controlled and attack-free for at least 6 months.
Option E: Option E is incorrect because lanadelumab reduces attack frequency across all HAE attack types (laryngeal, abdominal, cutaneous) rather than showing attack-site specificity; the drug works by reducing bradykinin generation systemically, and its efficacy is not limited to airway attacks.
9. A clinical pharmacist is counseling an HAE specialist on the differences among available C1 inhibitor products. Regarding recombinant human C1 inhibitor (rhC1-INH, Ruconest/conestat alfa), which of the following correctly identifies a key pharmacokinetic difference from plasma-derived C1-INH concentrates that determines its clinical use?
A) Ruconest has a half-life of approximately 30 to 40 hours — substantially longer than plasma-derived C1-INH — making it the preferred agent for long-term prophylaxis at twice-weekly subcutaneous dosing.
B) Ruconest is orally bioavailable because of its modified glycosylation pattern and can be taken as daily capsules for routine prophylaxis, avoiding the need for subcutaneous or intravenous administration in stable patients.
C) Ruconest has a substantially shorter half-life of approximately 3 hours compared with approximately 30 to 40 hours for plasma-derived C1-INH, which makes it suitable for acute attack treatment but not for prophylaxis at currently approved doses.
D) Ruconest has identical pharmacokinetics to plasma-derived C1-INH in adults but is preferred for pediatric use because its recombinant origin eliminates the theoretical risk of transfusion-transmitted infection that exists with pooled plasma products.
E) Ruconest is cleared exclusively by the kidneys rather than by hepatic metabolism, so its half-life is markedly prolonged in patients with renal impairment, necessitating dose reduction to avoid accumulation during prophylactic use.
ANSWER: C
Rationale:
Recombinant human C1 inhibitor (Ruconest, conestat alfa) is produced in the milk of transgenic rabbits and provides a non-plasma-derived source of C1 inhibitor for acute HAE attack treatment. Its key pharmacokinetic limitation is a substantially shorter half-life of approximately 3 hours compared with approximately 30 to 40 hours for plasma-derived C1-INH concentrates (Berinert, Cinryze). This short half-life means that the drug is rapidly eliminated, making it unsuitable for prophylaxis at currently approved doses because maintaining therapeutic C1-INH levels between dosing intervals would require inconveniently frequent administration. Ruconest is therefore approved only for acute attack treatment at a dose of 50 IU/kg intravenously, with a maximum of 4200 IU.
Option A: Option A is incorrect because the long half-life of 30 to 40 hours and twice-weekly subcutaneous dosing describes plasma-derived C1-INH (specifically HAEGARDA); Ruconest has the opposite pharmacokinetic profile — a short half-life — which is precisely why it is not used for prophylaxis.
Option B: Option B is incorrect because Ruconest is not orally bioavailable; as a protein, it is degraded by gastrointestinal enzymes and must be administered intravenously; no oral formulation of C1-INH exists for clinical use.
Option D: Option D is incorrect because Ruconest and plasma-derived C1-INH do not have identical pharmacokinetics in adults — the shorter half-life of Ruconest is a well-documented pharmacokinetic difference, and the clinical distinction is not primarily about pediatric versus adult use.
Option E: Option E is incorrect because renal elimination is not the primary clearance pathway for C1-INH proteins; the half-life difference between Ruconest and plasma-derived C1-INH is attributed primarily to differences in glycosylation pattern (Ruconest has high-mannose glycosylation that promotes rapid hepatic clearance via mannose receptors), not to renal clearance mechanisms.
10. An internal medicine resident managing a patient with long-standing HAE type I asks how danazol — an attenuated androgen used historically for HAE prophylaxis — reduces attack frequency. Which of the following best explains danazol's mechanism of action in this context?
A) Danazol competitively inhibits plasma kallikrein by binding to its active site, directly reducing the enzymatic generation of bradykinin from HMWK during contact activation events and thereby lowering the peak bradykinin concentration during attack triggers.
B) Danazol acts as a partial agonist at the bradykinin B1 receptor, producing submaximal stimulation that desensitizes the receptor and reduces its responsiveness to the full B1 agonist des-Arg9-bradykinin generated during HAE attacks.
C) Danazol binds to the androgen receptor on vascular endothelial cells and directly downregulates B2 receptor gene expression, reducing the density of bradykinin receptors at vascular surfaces and attenuating the vascular permeability response to any bradykinin generated.
D) Danazol inhibits factor XII activation by stabilizing contact system proteins in their zymogen (inactive) forms, preventing the initial trigger of the kallikrein-kinin cascade when factor XII encounters negatively charged surfaces at attack sites.
E) Danazol acts through hepatic androgen receptor activation to upregulate the transcription of the C1-INH gene, increasing plasma C1-INH levels and activity into or above the normal range in responsive patients and thereby restoring physiological inhibition of plasma kallikrein.
ANSWER: E
Rationale:
Danazol is an attenuated synthetic androgen that exerts its HAE prophylactic effect through hepatic androgen receptor activation, which upregulates expression of the SERPING1 gene encoding C1 inhibitor. The resulting increase in hepatic C1-INH synthesis raises plasma C1-INH levels and functional activity into or above the normal physiological range in responsive patients, restoring the regulatory brake on plasma kallikrein and reducing the frequency and severity of HAE attacks. This mechanism is entirely indirect — danazol does not interact with kallikrein, bradykinin receptors, or contact system proteins directly.
Option A: Option A is incorrect because danazol does not inhibit plasma kallikrein directly; direct kallikrein inhibition is the mechanism of ecallantide and lanadelumab — danazol's effect on kallikrein activity is entirely secondary to its upregulation of C1-INH.
Option B: Option B is incorrect because danazol has no pharmacological activity at bradykinin receptors; B1 receptor partial agonism is not a recognized mechanism of any approved HAE drug, and this option incorrectly frames receptor desensitization as danazol's mode of action.
Option C: Option C is incorrect because androgen receptor-mediated downregulation of B2 receptor gene expression at vascular endothelium is not a documented mechanism of danazol or any attenuated androgen in clinical use; danazol's target is hepatic C1-INH gene transcription, not endothelial receptor modulation.
Option D: Option D is incorrect because stabilization of factor XII in its zymogen form is not a mechanism of danazol; factor XII inhibition describes garadacimab's mechanism; danazol does not interact with factor XII or stabilize contact system proteins.
11. A 26-year-old woman with HAE type I has been stable on danazol prophylaxis for 3 years. She informs her physician that she and her partner are planning a pregnancy. Which of the following represents the correct management decision regarding her danazol therapy?
A) Danazol should be continued at the lowest effective dose during the first trimester because abrupt withdrawal risks a severe rebound HAE attack; the dose should then be tapered in the second trimester when estrogen levels rise and attack frequency typically increases.
B) Danazol must be discontinued before conception because it is absolutely contraindicated in pregnancy due to androgenic teratogenicity — virilization of a female fetus is a well-documented risk — and alternative prophylaxis with plasma-derived C1-INH concentrate should be substituted.
C) Danazol may be continued during pregnancy with dose reduction to 100 mg daily because the fetal androgenic risk is limited to the first trimester and the drug has an acceptable safety profile during the second and third trimesters when fetal organogenesis is complete.
D) Danazol can be safely continued during pregnancy without dose adjustment because the placenta metabolizes danazol to inactive compounds before they reach the fetal circulation, effectively preventing androgenic exposure to the developing fetus.
E) Danazol should be replaced with tranexamic acid during pregnancy because tranexamic acid has a superior efficacy profile to C1-INH concentrates in pregnant patients with HAE and is the treatment of choice endorsed by current HAE guidelines for obstetric patients.
ANSWER: B
Rationale:
Danazol is absolutely contraindicated in pregnancy because of its androgenic teratogenicity. Exposure of a female fetus to danazol during pregnancy has been documented to cause virilization — including clitoral hypertrophy, labioscrotal fusion, and other androgenic effects on the external genitalia. Because this risk is serious and the contraindication is absolute, danazol must be discontinued before conception. The appropriate alternative for HAE prophylaxis during pregnancy is plasma-derived C1-INH concentrate, which is safe in pregnancy and is the treatment of choice endorsed by current HAE guidelines for both prophylaxis and acute attack treatment in pregnant patients.
Option A: Option A is incorrect because continuing danazol into pregnancy in any trimester is absolutely contraindicated; there is no first-trimester continuation strategy, and the claim that abrupt withdrawal causes rebound attacks does not override the teratogenic risk or the availability of safe C1-INH alternatives.
Option C: Option C is incorrect because androgenic teratogenicity is not limited to the first trimester; fetal virilization can occur with androgenic exposure at multiple developmental stages, and no trimester of danazol use is considered safe in pregnancy.
Option D: Option D is incorrect because the premise that placental metabolism inactivates danazol before fetal exposure is not established; danazol does cross the placenta, and the documented cases of fetal virilization confirm active androgenic fetal exposure in utero.
Option E: Option E is incorrect because tranexamic acid is not endorsed as a first-line or superior agent for HAE management in pregnancy; tranexamic acid has less efficacy than C1-INH concentrates for HAE prophylaxis and its safety in pregnancy specifically for HAE management does not supersede the established safety record of C1-INH concentrates, which are the guideline-endorsed first choice.
12. A 38-year-old man with HAE type II is scheduled for elective cholecystectomy under general anesthesia. His HAE specialist advises the surgical team on short-term prophylaxis (STP) to prevent a perioperative HAE attack. Which of the following correctly identifies the preferred approach to STP for major elective surgery in HAE patients?
A) Plasma-derived C1 inhibitor concentrate (pdC1-INH) administered intravenously 1 to 6 hours before the procedure is the preferred short-term prophylactic agent for major elective surgery in HAE patients; fresh frozen plasma is a second-line alternative when C1-INH concentrate is unavailable.
B) Fresh frozen plasma (FFP) is the preferred agent for surgical short-term prophylaxis in HAE because it contains all three principal contact system proteins — C1-INH, HMWK, and prekallikrein — simultaneously, providing broader system-level correction than C1-INH concentrate alone.
C) Oral danazol begun on the morning of surgery at a loading dose of 600 mg is the preferred prophylactic approach because it acts within hours to upregulate hepatic C1-INH synthesis, providing effective protection by the time the surgical procedure begins.
D) No short-term prophylaxis is necessary for elective surgery if the patient has been attack-free for more than 6 months on a current long-term prophylactic regimen, because the underlying HAE is considered adequately controlled and surgical stress does not independently trigger HAE attacks.
E) Icatibant administered subcutaneously 30 minutes before the surgical incision is the preferred short-term prophylaxis agent because its rapid onset at the B2 receptor provides immediate protection against the kallikrein activation triggered by surgical trauma and endotracheal intubation.
ANSWER: A
Rationale:
Plasma-derived C1 inhibitor concentrate is the preferred agent for short-term prophylaxis before major surgical procedures in HAE patients. The recommended dose (Berinert or Cinryze) is administered intravenously 1 to 6 hours before the procedure, providing circulating C1-INH levels above the threshold needed to inhibit any kallikrein activation triggered by surgical trauma. FFP is recognized as an alternative when C1-INH concentrate is unavailable, but it is a second-line option: FFP also contains HMWK (the bradykinin precursor), which means it could paradoxically worsen some HAE attacks by providing additional substrate for any residual kallikrein activity, and it carries transfusion-related risks that C1-INH concentrates avoid.
Option B: Option B is incorrect because FFP's inclusion of HMWK — the bradykinin precursor — is actually a liability in HAE rather than an advantage; it can paradoxically worsen attacks by increasing substrate availability for kallikrein, which is why FFP is explicitly a second-line option rather than the preferred agent.
Option C: Option C is incorrect because oral danazol requires 5 to 7 days of pre-procedural dosing to meaningfully upregulate hepatic C1-INH synthesis — it cannot produce adequate protection when started on the day of surgery; danazol may be used for STP when given for 5 to 7 days before an elective procedure, not as a same-day loading dose.
Option D: Option D is incorrect because surgical trauma, endotracheal intubation, and emotional stress are recognized HAE triggers that can precipitate attacks even in patients who are well-controlled on prophylaxis; HAE guidelines recommend STP for major procedures regardless of the patient's recent attack frequency or prophylactic status.
Option E: Option E is incorrect because icatibant is an acute treatment for ongoing attacks, not a prophylactic agent; it has a short half-life of 1 to 2 hours and blocking the B2 receptor pre-emptively is not the appropriate prophylactic strategy — the goal is to maintain adequate C1-INH levels to prevent kallikrein activation from occurring in the first place.
13. A 22-year-old woman with HAE type I reports that her attacks have significantly increased in frequency since she started a combined oral contraceptive containing ethinylestradiol. Her HAE specialist explains the pharmacological basis for estrogen's role as an attack trigger. Which of the following correctly describes why estrogen exposure worsens HAE?
A) Estrogen is a direct agonist at the bradykinin B2 receptor and at low concentrations mimics the vascular permeability effects of bradykinin, producing endothelial activation and submucosal edema independently of the kallikrein-kinin cascade.
B) Estrogen competitively inhibits the binding of C1-INH to plasma kallikrein, directly reducing C1-INH's ability to form covalent inhibitory complexes with its target serine proteases and thereby releasing kallikrein from physiological inhibitory control.
C) Estrogen upregulates hepatic HMWK gene expression — increasing the availability of the bradykinin precursor substrate — while simultaneously downregulating hepatic C1-INH synthesis, creating a dual vulnerability in which more substrate is available for kallikrein while less inhibitor is present to restrain it.
D) Estrogen activates the classical complement pathway through direct binding to C1q, causing C1s-mediated cleavage of C4 and C2 that overwhelms residual C1-INH activity and secondarily increases kallikrein generation through an amplification loop linking complement and contact activation.
E) Estrogen suppresses the hepatic synthesis of prekallikrein, paradoxically raising plasma kallikrein activity by eliminating the competitive substrate competition between prekallikrein and HMWK and allowing HMWK to be cleaved more rapidly during contact activation.
ANSWER: C
Rationale:
Estrogen worsens HAE through a dual pharmacological mechanism acting at the hepatic level: it upregulates transcription of the HMWK gene, increasing plasma levels of high-molecular-weight kininogen (the substrate from which bradykinin is cleaved by kallikrein), while simultaneously downregulating hepatic C1-INH synthesis, reducing the plasma C1-INH activity available to restrain kallikrein. The net result is that more bradykinin substrate is available at the same time that less kallikrein inhibition exists — a combination that dramatically increases attack susceptibility during estrogen exposure. This mechanism explains why HAE attacks worsen during pregnancy (rising estrogen), with combined oral contraceptives containing ethinylestradiol, and with hormone replacement therapy. Progestin-only contraceptives, which do not substantially raise estrogen levels, are generally tolerated in HAE patients.
Option A: Option A is incorrect because estrogen does not act as a direct B2 receptor agonist; the B2 receptor's natural ligand is bradykinin, and estrogen exerts its HAE effects through hepatic gene regulation rather than direct receptor binding.
Option B: Option B is incorrect because estrogen does not competitively inhibit C1-INH binding to kallikrein at the enzyme level; C1-INH forms covalent inhibitory complexes with its target serine proteases through a serpin mechanism, and estrogen does not interfere with this covalent chemistry; estrogen's effect on C1-INH is at the gene transcription level, not the protein-protein interaction level.
Option D: Option D is incorrect because estrogen does not directly bind C1q or activate the classical complement pathway; the complement pathway is regulated by C1-INH but estrogen-driven HAE worsening is mediated through HMWK and C1-INH gene regulation, not through complement C1q activation.
Option E: Option E is incorrect because estrogen does not suppress prekallikrein synthesis; the mechanism described misrepresents how the contact system operates and does not reflect any established pharmacological action of estrogen on prekallikrein gene expression.
14. A cardiology fellow reviews the pharmacology of sacubitril-valsartan (Entresto) before prescribing it to a patient with heart failure with reduced ejection fraction (HFrEF — a condition in which the heart pumps less than normal, defined as ejection fraction below 40%). She wants to understand which enzyme sacubitril inhibits and how it reaches its active form. Which of the following correctly describes sacubitril's mechanism and pharmacokinetic activation?
A) Sacubitril directly inhibits angiotensin-converting enzyme (ACE) in its parent form without requiring metabolic activation, providing combined RAAS inhibition alongside the ARB valsartan and thereby blocking two separate steps in the renin-angiotensin system simultaneously.
B) Sacubitril is a direct-acting inhibitor of plasma kallikrein that is active as administered, reducing bradykinin generation from HMWK and thereby decreasing the bradykinin-mediated vasodilation that contributes to the neurohormonal activation of heart failure.
C) Sacubitril inhibits natriuretic peptide receptor-A (NPR-A) at the cell surface of cardiomyocytes and renal tubular cells, blocking the downstream cyclic GMP signaling that promotes natriuresis and cardioprotection in heart failure.
D) Sacubitril is a prodrug that is converted by esterases in vivo to its active metabolite LBQ657, which inhibits neprilysin — a zinc metallopeptidase that degrades natriuretic peptides (ANP and BNP) — thereby increasing circulating natriuretic peptide levels and enhancing natriuresis, vasodilation, and cardioprotection.
E) Sacubitril is a competitive inhibitor of angiotensin II at the AT1 receptor, producing vasodilation and aldosterone suppression through the same mechanism as ARBs such as valsartan, with the AT2 receptor agonism of sacubitril providing additional cardioprotective natriuretic effects not shared by valsartan.
ANSWER: D
Rationale:
Sacubitril is a prodrug — it is pharmacologically inactive as administered and must be converted by plasma esterases to its active metabolite LBQ657. LBQ657 inhibits neprilysin (neutral endopeptidase 24.11, also designated CD10 or enkephalinase), a zinc metallopeptidase expressed on the kidney, lung, heart, and vascular endothelium. Neprilysin's principal cardiovascular substrates are the natriuretic peptides ANP and BNP, which promote natriuresis, vasodilation, and anti-fibrotic effects. When neprilysin is inhibited, ANP and BNP levels rise, potentiating these cardioprotective effects. Sacubitril is combined with valsartan (an ARB) rather than an ACE inhibitor, because simultaneous neprilysin and ACE inhibition would cause excessive bradykinin accumulation.
Option A: Option A is incorrect because sacubitril does not inhibit ACE; it inhibits neprilysin, an entirely different enzyme; combining sacubitril with an ACEI rather than an ARB would create dangerous synergistic bradykinin accumulation, which is why the combination is absolutely contraindicated.
Option B: Option B is incorrect because sacubitril does not inhibit plasma kallikrein; kallikrein inhibition is the mechanism of ecallantide (for HAE) and investigational agents; sacubitril acts on a bradykinin-degrading enzyme (neprilysin), not on a bradykinin-generating enzyme.
Option C: Option C is incorrect because sacubitril does not inhibit natriuretic peptide receptor-A; NPR-A is the receptor that responds to ANP and BNP, and sacubitril works by increasing the ligands (ANP and BNP) that activate this receptor, not by blocking the receptor itself.
Option E: Option E is incorrect because sacubitril does not block the AT1 receptor; AT1 receptor antagonism is the mechanism of valsartan (the ARB component of Entresto), not sacubitril; sacubitril acts on neprilysin, a proteolytic enzyme, not on an angiotensin receptor.
15. A medical student studying the pharmacology of sacubitril-valsartan asks her attending which peptides neprilysin normally degrades that are relevant to its cardiovascular effects. Which of the following correctly identifies the principal neprilysin substrates whose increased levels drive the cardiovascular benefits of sacubitril?
A) Neprilysin principally degrades angiotensin II and aldosterone in plasma, and sacubitril's benefit in heart failure derives from the resulting reduction in vasoconstriction and sodium retention when these vasoconstrictive hormones are allowed to accumulate less rapidly.
B) Neprilysin principally degrades endothelin-1 and substance P at vascular endothelial surfaces; sacubitril raises endothelin-1 and substance P levels, and the resulting vasodilation and natriuresis from elevated substance P signaling at renal tubular cells accounts for the drug's cardiovascular benefit.
C) Neprilysin principally degrades bradykinin and des-Arg9-bradykinin; sacubitril raises bradykinin levels as its primary therapeutic mechanism, and the bradykinin-mediated vasodilation and natriuresis — identical in mechanism to ACE inhibitor benefit — accounts for the cardiovascular improvements seen in PARADIGM-HF.
D) Neprilysin principally degrades angiotensin 1-7, and sacubitril raises angiotensin 1-7 levels by impairing its neprilysin-mediated breakdown, producing vasodilation through Mas receptor activation and anti-fibrotic effects at the myocardium that complement the ARB component of the fixed-dose combination.
E) Neprilysin principally degrades atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) in the cardiovascular context; sacubitril raises circulating ANP and BNP levels, potentiating natriuresis, vasodilation, and anti-fibrotic cardioprotective effects that are the primary therapeutic mechanism in HFrEF.
ANSWER: E
Rationale:
The principal cardiovascular substrates of neprilysin are the natriuretic peptides — atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). These peptides are released by cardiac chambers in response to volume overload and elevated filling pressures, and they promote natriuresis, vasodilation, and inhibition of cardiac fibrosis. In heart failure, endogenous natriuretic peptide levels are elevated as a compensatory response, but this response is attenuated because neprilysin activity also increases. When sacubitril inhibits neprilysin, ANP and BNP levels rise further, potentiating these cardioprotective effects. The PARADIGM-HF trial demonstrated that sacubitril-valsartan reduced cardiovascular death and heart failure hospitalization by 20% relative to enalapril, with natriuretic peptide augmentation as the primary mechanistic driver.
Option A: Option A is incorrect because angiotensin II and aldosterone are not neprilysin substrates; angiotensin II is generated by ACE and degraded by angiotensinases and ACE2, not neprilysin; sacubitril does not affect angiotensin II or aldosterone levels through a direct degradation pathway.
Option B: Option B is incorrect because while neprilysin can degrade substance P and endothelin-1, these are not the principal substrates through which sacubitril exerts its cardiovascular benefit; the therapeutic mechanism is natriuretic peptide augmentation, not substance P or endothelin-1 accumulation.
Option C: Option C is incorrect because bradykinin augmentation is a secondary effect of neprilysin inhibition — bradykinin is also a neprilysin substrate — but it is not the primary therapeutic mechanism; elevated bradykinin from sacubitril is actually an adverse effect risk (contributing to angioedema), not the mechanism of cardiovascular benefit; the correct primary substrates are ANP and BNP.
Option D: Option D is incorrect because angiotensin 1-7 is a substrate of ACE2, not primarily of neprilysin; while some overlap exists, Mas receptor activation by angiotensin 1-7 is not the established primary mechanism of sacubitril's cardiovascular benefit.
16. A hospitalist transitions a patient with HFrEF from enalapril to sacubitril-valsartan and is counseled by the pharmacist that combining sacubitril-valsartan with any ACE inhibitor (ACEI — a drug class that blocks the enzyme angiotensin-converting enzyme) is absolutely contraindicated. Which of the following best explains the pharmacological basis for this contraindication?
A) Combining sacubitril with an ACEI produces additive AT1 receptor blockade because both agents independently reduce angiotensin II signaling — sacubitril through neprilysin inhibition and the ACEI through ACE inhibition — resulting in dangerous hypotension and acute kidney injury from excessive RAAS suppression.
B) Sacubitril inhibits neprilysin, one of the principal pathways for bradykinin degradation, while ACE inhibitors block ACE (kininase II), another major bradykinin-clearing enzyme; combining both agents simultaneously blocks two of the three main bradykinin-clearing mechanisms, causing synergistic bradykinin accumulation and substantially increasing the risk of angioedema.
C) Sacubitril-valsartan contains an ARB (valsartan) that competitively antagonizes AT1 receptors at the same binding site as ACE inhibitors, producing a pharmacodynamic interaction in which each drug displaces the other from the receptor and results in unpredictable and erratic angiotensin II blockade.
D) Combining sacubitril with an ACEI produces additive neprilysin inhibition because many ACE inhibitors are also weak neprilysin inhibitors at therapeutic concentrations, resulting in excessive natriuretic peptide accumulation that causes dangerous hypotension through unopposed vasodilation.
E) The combination is contraindicated because ACE inhibitors deplete the plasma prekallikrein pool needed to generate the active plasma kallikrein that sacubitril depends on to exert its anti-bradykinin effect, rendering sacubitril pharmacologically inactive when co-administered with an ACEI.
ANSWER: B
Rationale:
The absolute contraindication of sacubitril-valsartan with ACE inhibitors is rooted in synergistic bradykinin accumulation. Bradykinin is normally cleared by three principal mechanisms: ACE (kininase II), neprilysin, and carboxypeptidase N. Sacubitril inhibits neprilysin, blocking one of these clearance pathways. ACE inhibitors block ACE (kininase II), blocking a second major clearance pathway. When both are used simultaneously, two of the three main bradykinin-clearing mechanisms are disabled, producing a substantially greater elevation in tissue bradykinin than either agent alone. The clinical consequence is a markedly increased risk of angioedema, which can be severe and airway-threatening. This pharmacodynamic interaction is precisely why sacubitril-valsartan contains valsartan (an ARB, which does not affect bradykinin clearance) rather than an ACEI — the combination is intentionally designed to avoid this interaction.
Option A: Option A is incorrect because sacubitril does not produce AT1 receptor blockade or affect angiotensin II signaling directly; neprilysin inhibition raises natriuretic peptides, which have vasodilatory and natriuretic effects through their own receptors (NPR-A), not through AT1 blockade; the contraindication is not about additive RAAS suppression but about bradykinin accumulation.
Option C: Option C is incorrect because valsartan (an ARB) and ACE inhibitors act at different molecular targets — ARBs block the AT1 receptor while ACEIs inhibit the converting enzyme — they do not compete for the same binding site, and there is no receptor-displacement interaction between them.
Option D: Option D is incorrect because ACE inhibitors are not clinically significant neprilysin inhibitors at therapeutic concentrations; the premise that ACEIs contribute meaningful neprilysin inhibition that adds to sacubitril's effect is pharmacologically incorrect — their mechanism is ACE inhibition, not neprilysin inhibition.
Option E: Option E is incorrect because sacubitril does not depend on prekallikrein or plasma kallikrein for its mechanism; sacubitril inhibits neprilysin and does not interact with the contact activation system; the premise misattributes an anti-bradykinin effect to sacubitril, which actually raises bradykinin (not lowers it) by blocking one of its degradation enzymes.
17. A cardiologist is transitioning a patient from enalapril to sacubitril-valsartan and explains to the team why a 36-hour washout period is required between the last ACEI dose and the first dose of sacubitril-valsartan. Which of the following correctly explains the pharmacokinetic basis for the 36-hour washout requirement?
A) The 36-hour washout is based on the half-life of enalaprilat — the active metabolite of enalapril — which is approximately 11 hours; 36 hours represents approximately 3 to 4 half-lives, sufficient time to reduce residual ACEI activity to a level at which the risk of synergistic bradykinin accumulation with sacubitril is acceptably low.
B) The 36-hour washout is based on the half-life of LBQ657, the active sacubitril metabolite, which is approximately 36 hours; the washout ensures that sacubitril is fully eliminated before the ACEI is re-introduced, preventing the two drugs from overlapping during the reversal transition.
C) The 36-hour washout period was established empirically based on the time required for vascular endothelial bradykinin B2 receptors to return to their baseline expression level after the receptor downregulation produced by sustained bradykinin elevation during prior ACEI therapy.
D) The 36-hour washout is based on the elimination half-life of valsartan (approximately 9 to 13 hours), which limits its interaction with ACEIs through competition for the same hepatic CYP3A4 metabolic pathway and requires washout to avoid a pharmacokinetic drug-drug interaction at the metabolic level.
E) The 36-hour washout requirement is based on the time required for complement C4 levels to normalize after ACEI-induced complement activation; before C4 returns to baseline, any additional bradykinin elevation from neprilysin inhibition is amplified by residual complement dysregulation and produces disproportionate vascular permeability.
ANSWER: A
Rationale:
The 36-hour washout requirement between the last ACEI dose and the first dose of sacubitril-valsartan is pharmacokinetically derived from the half-lives of commonly used ACE inhibitors. Enalaprilat — the active metabolite of enalapril — has a half-life of approximately 11 hours, so 36 hours represents approximately 3.3 half-lives. Lisinopril, which has a longer half-life of approximately 12 hours, falls within the same general window. After 3 to 4 half-lives, residual ACEI activity is reduced to a level at which the risk of synergistic bradykinin accumulation when sacubitril is added is acceptably low. The same 36-hour washout applies in the reverse direction (transitioning from sacubitril-valsartan back to an ACEI) because LBQ657, the active sacubitril metabolite, also has a half-life of approximately 11 to 12 hours.
Option B: Option B is incorrect because while LBQ657 does have a half-life of approximately 11 to 12 hours, the 36-hour washout is required when adding sacubitril to a patient who was on an ACEI — the washout is for the ACEI, not for sacubitril; the same logic applies in reverse (ACEI after sacubitril), but the washout rationale is ACEI half-life based in either direction.
Option C: Option C is incorrect because bradykinin B2 receptor expression levels and their return to baseline after ACEI-mediated bradykinin elevation are not the pharmacokinetic basis for the 36-hour washout; the washout is defined by ACEI plasma levels (determined by half-life), not by receptor re-expression kinetics.
Option D: Option D is incorrect because the 36-hour washout is not based on valsartan's pharmacokinetics or CYP3A4 metabolism; the washout specifically addresses the bradykinin interaction risk when ACEI activity overlaps with neprilysin inhibition, not a pharmacokinetic drug-drug interaction at the metabolic enzyme level involving valsartan.
Option E: Option E is incorrect because complement C4 levels and complement activation are not the basis for the 36-hour washout; C4 is consumed in HAE attacks through the classical complement pathway, but in the context of ACEI-to-sacubitril transitions, the washout rationale is entirely about bradykinin accumulation risk, not complement normalization.
18. A cardiology fellow presenting a journal club review of PARADIGM-HF is asked about angioedema rates in that trial and which patient populations are at highest risk for sacubitril-valsartan-associated angioedema. Which of the following correctly summarizes the angioedema data from PARADIGM-HF and the clinical groups at elevated risk?
A) Angioedema occurred at identical rates in both arms of PARADIGM-HF (0.45% in each group), establishing that the angioedema risk of sacubitril-valsartan is not meaningfully greater than that of ACE inhibitor therapy and confirming that the 36-hour washout requirement is sufficient to eliminate the incremental risk.
B) Angioedema in PARADIGM-HF occurred exclusively in patients of African American ancestry in both the sacubitril-valsartan and enalapril arms, with no angioedema events recorded in patients of other racial backgrounds, establishing African American ancestry as a necessary rather than additive risk factor.
C) Angioedema was not observed in any patient in the sacubitril-valsartan arm of PARADIGM-HF because the trial excluded patients with prior ACEI-induced angioedema; the clinical risk of sacubitril-valsartan-associated angioedema is therefore entirely theoretical and has not been demonstrated in prospective trial data.
D) In PARADIGM-HF, angioedema occurred in 0.45% of sacubitril-valsartan patients versus 0.24% of enalapril patients — a statistically significant difference — with African American patients showing substantially higher rates in both arms; the three patient groups at highest angioedema risk with sacubitril-valsartan are those with prior ACEI-induced angioedema, African American patients, and those who receive sacubitril within 36 hours of their last ACEI dose.
E) Angioedema occurred in 4.5% of sacubitril-valsartan patients in PARADIGM-HF, representing a tenfold increase over the 0.45% rate observed with enalapril, reflecting the additive effect of simultaneous AT1 receptor blockade and neprilysin inhibition on vascular permeability at mucosal surfaces.
ANSWER: D
Rationale:
In PARADIGM-HF, angioedema occurred in 0.45% of sacubitril-valsartan patients versus 0.24% of enalapril patients over a median follow-up of 27 months, a statistically significant difference reflecting the additive bradykinin elevation produced by neprilysin inhibition on top of baseline susceptibility. African American patients had higher rates in both arms (approximately 2.4% with sacubitril-valsartan versus 0.5% with enalapril), consistent with the known racial disparity in bradykinin-mediated angioedema susceptibility. The three clinical groups at highest risk are: patients with prior ACEI-induced angioedema (in whom bradykinin-mediated susceptibility is established, and sacubitril-valsartan is generally considered contraindicated); African American patients (higher baseline susceptibility); and patients who receive sacubitril within 36 hours of their last ACEI dose (synergistic dual pathway blockade).
Option A: Option A is incorrect because the angioedema rates were not identical between arms — 0.45% with sacubitril-valsartan versus 0.24% with enalapril represents a statistically significant doubling of events, demonstrating that sacubitril-valsartan does carry incremental angioedema risk relative to enalapril.
Option B: Option B is incorrect because angioedema occurred in patients of multiple racial backgrounds in PARADIGM-HF, not exclusively in African American patients; African American ancestry is an additive risk factor that increases absolute rates in both arms but is not a necessary condition for angioedema to occur.
Option C: Option C is incorrect because angioedema events did occur in the sacubitril-valsartan arm of PARADIGM-HF (0.45% of patients), demonstrating real clinical risk; while the trial did exclude patients with prior ACEI-induced angioedema, this exclusion means the true risk in that higher-susceptibility population is underestimated by the trial data, not that the risk is absent.
Option E: Option E is incorrect because the angioedema rate in PARADIGM-HF was 0.45% with sacubitril-valsartan, not 4.5%; a tenfold higher rate would represent an unacceptably dangerous drug that would not have received FDA approval; the actual absolute risk is low, though statistically significantly higher than with enalapril.
19. A pain medicine fellow studying the pharmacology of inflammatory hyperalgesia reviews how bradykinin contributes to peripheral sensitization. Which of the following correctly describes the mechanism by which bradykinin amplifies pain signaling at peripheral sensory neurons in inflammatory states such as rheumatoid arthritis or postoperative pain?
A) Bradykinin crosses the blood-nerve barrier and acts centrally at B2 receptors in the dorsal horn of the spinal cord, directly inhibiting GABA-ergic interneurons that normally suppress pain transmission and thereby producing disinhibition of ascending nociceptive pathways.
B) Bradykinin activates B2 receptors on peripheral sensory neurons and triggers Gs-protein-coupled adenylyl cyclase activation, raising intracellular cAMP and phosphorylating sodium channels through protein kinase A — the same sensitization pathway activated by prostaglandins released from cyclooxygenase in inflamed tissue.
C) Bradykinin activates B2 receptors on peripheral sensory neurons, triggering downstream protein kinase C (PKC) activation that phosphorylates TRPV1 and TRPA1 ion channels (temperature and chemical nociceptors), lowering their thermal activation thresholds and amplifying responses to other inflammatory mediators — a process called peripheral sensitization.
D) Bradykinin produces peripheral sensitization by acting as a direct substrate for cyclooxygenase-2 (COX-2) in inflamed tissue, where it is converted to a bradykinin-prostaglandin hybrid eicosanoid that has greater affinity for nociceptor ion channels than either bradykinin or prostaglandins alone.
E) Bradykinin activates B1 receptors on mast cells at peripheral inflammatory sites, triggering degranulation and histamine release that secondarily sensitizes nearby TRPV1-expressing nociceptors through histamine H1 receptor coupling, with the sensitization being indirect and dependent on mast cell involvement.
ANSWER: C
Rationale:
Bradykinin is among the most potent endogenous algogens, producing intense pain at nanomolar concentrations when applied to peripheral sensory endings. Its mechanism of peripheral sensitization involves B2 receptor activation on nociceptive (pain-sensing) neurons, which activates phospholipase C and downstream protein kinase C (PKC). PKC then phosphorylates TRPV1 (the transient receptor potential vanilloid 1 channel, a thermal and chemical nociceptor) and TRPA1 (a mechanochemical nociceptor), lowering their activation thresholds and making the sensory neuron more responsive to thermal and chemical stimuli. This process — peripheral sensitization — is the molecular basis of inflammatory hyperalgesia, where previously non-painful stimuli become painful (allodynia) and mildly painful stimuli become severely painful (hyperalgesia). The B1 receptor, upregulated by cytokines at chronic inflammation sites, mediates sustained sensitization that does not desensitize.
Option A: Option A is incorrect because bradykinin acts primarily at peripheral sensory endings rather than crossing the blood-nerve barrier in significant amounts to act centrally in the dorsal horn; central bradykinin pharmacology exists but the peripheral B2-PKC-TRPV1 mechanism is the established primary mechanism of inflammatory hyperalgesia; the description of GABA-ergic disinhibition is not the correct mechanism.
Option B: Option B is incorrect because bradykinin's peripheral sensitization mechanism involves PKC activation through Gq-coupled signaling (phospholipase C pathway), not Gs-coupled adenylyl cyclase and protein kinase A; the cAMP/PKA pathway is used by prostaglandins (notably PGE2 acting at EP receptors) for sensitization, not by bradykinin.
Option D: Option D is incorrect because bradykinin is not a substrate for cyclooxygenase; COX enzymes act on arachidonic acid to produce prostaglandins and thromboxanes — they do not process peptides such as bradykinin; no bradykinin-prostaglandin hybrid exists as a recognized pharmacological entity.
Option E: Option E is incorrect because while B1 receptors do contribute to chronic inflammatory pain, the mechanism described — mast cell degranulation with histamine-mediated TRPV1 sensitization — is not the established mechanism of bradykinin's pain-sensitizing effect; bradykinin acts directly on nociceptors through B2 receptor activation, not indirectly through mast cell histamine release.
20. A pulmonologist interested in COVID-19 pathophysiology asks about the bradykinin hypothesis proposed to explain the severe pulmonary edema and vascular permeability seen in COVID-19 acute respiratory distress syndrome (ARDS — a condition of severe lung inflammation and hypoxemia requiring ICU-level respiratory support). Which of the following correctly summarizes the mechanistic basis of the COVID-19 bradykinin hypothesis?
A) SARS-CoV-2 directly activates plasma kallikrein by binding to prekallikrein through its spike protein, triggering a kallikrein storm that generates massive bradykinin concentrations in the pulmonary vasculature that overwhelm ACE2-mediated clearance and cause catastrophic pulmonary edema.
B) SARS-CoV-2 upregulates ACE2 expression on pulmonary vascular endothelium — rather than downregulating it — causing excessive degradation of angiotensin II and diversion of angiotensin 1-7 production toward bradykinin formation through a non-canonical kinin synthesis pathway activated specifically in COVID-19 pneumonia.
C) The bradykinin hypothesis proposes that SARS-CoV-2-induced complement activation through the lectin pathway consumes C1-INH at pulmonary surfaces, releasing plasma kallikrein from inhibitory control and generating a kallikrein-bradykinin storm in the alveolar compartment that is mechanistically identical to a systemic HAE attack.
D) SARS-CoV-2 infects pulmonary mast cells and triggers histamine and bradykinin co-release, with bradykinin acting at B2 receptors and histamine acting at H1 receptors simultaneously on pulmonary endothelial cells, producing an additive vascular permeability increase that is the defining mechanism of COVID-19 pulmonary edema.
E) The bradykinin hypothesis proposes that SARS-CoV-2 enters cells via ACE2 and downregulates ACE2 expression in the process; ACE2 (distinct from ACE) normally degrades des-Arg9-bradykinin — the primary B1 receptor agonist — so ACE2 depletion allows des-Arg9-bradykinin to accumulate, and combined with cytokine-storm-driven B1 receptor upregulation, produces progressive pulmonary vascular permeability through sustained B1 signaling.
ANSWER: E
Rationale:
The COVID-19 bradykinin hypothesis centers on the consequences of SARS-CoV-2 using ACE2 as its cellular receptor. ACE2 (angiotensin-converting enzyme 2) is a carboxypeptidase that is distinct from ACE; one of its substrates is des-Arg9-bradykinin, the primary endogenous agonist at the B1 receptor (formed from bradykinin by carboxypeptidase N). When SARS-CoV-2 binds to and is internalized through ACE2, it downregulates cell-surface ACE2 expression at the lung endothelium — reducing the clearance of des-Arg9-bradykinin. Simultaneously, the cytokine storm of severe COVID-19 upregulates B1 receptor expression (as cytokines do at sites of inflammation). The combination — more B1 receptor agonist accumulating due to impaired ACE2-mediated clearance, and more B1 receptors to respond to it — produces progressive pulmonary microvascular permeability that may contribute to the distinctive alveolar edema of COVID-19 ARDS. This hypothesis remains investigational; clinical trials of bradykinin-targeting agents in COVID-19 have not yet demonstrated clear benefit.
Option A: Option A is incorrect because SARS-CoV-2 does not directly activate prekallikrein through spike protein binding; the bradykinin hypothesis does not involve a direct spike-prekallikrein interaction; it centers instead on ACE2 depletion and its effect on des-Arg9-bradykinin clearance.
Option B: Option B is incorrect because SARS-CoV-2 downregulates ACE2 rather than upregulating it; increased ACE2 would actually accelerate des-Arg9-bradykinin clearance rather than causing accumulation; the hypothesis depends on ACE2 loss, not gain.
Option C: Option C is incorrect because the COVID-19 bradykinin hypothesis does not center on C1-INH consumption or lectin-pathway complement activation releasing kallikrein; while complement is activated in severe COVID-19, the specific bradykinin hypothesis described in the transcriptomic analyses focuses on ACE2 depletion and B1 agonist accumulation, not on a HAE-type kallikrein storm.
Option D: Option D is incorrect because mast cell co-release of histamine and bradykinin is not the mechanistic basis of the COVID-19 bradykinin hypothesis; the hypothesis is specific to the ACE2-des-Arg9-bradykinin-B1 receptor axis and does not involve histamine-bradykinin co-release from pulmonary mast cells.
21. An HAE specialist at a multidisciplinary conference presents emerging pipeline therapies. She describes donidalorsen, a novel prophylactic agent in late-stage clinical development at the time. Which of the following correctly describes donidalorsen's mechanism and clinical significance?
A) Donidalorsen is an oral small-molecule inhibitor of plasma kallikrein that can be taken at the onset of an acute HAE attack, offering a needle-free alternative to currently available injectable acute treatments such as icatibant and ecallantide.
B) Donidalorsen is a subcutaneously administered monoclonal antibody that targets factor XIIa — the contact activation trigger upstream of kallikrein — and is used for long-term HAE prophylaxis rather than acute attack treatment, with a dosing interval of once monthly.
C) Donidalorsen is an intravenous recombinant human C1 inhibitor concentrate that has been engineered with a prolonged half-life of approximately 72 hours to allow weekly prophylactic dosing in patients who do not respond to standard pdC1-INH products with their shorter half-lives.
D) Donidalorsen is an RNA-targeted antisense oligonucleotide administered subcutaneously (approximately every 4 to 8 weeks) that reduces hepatic synthesis of prekallikrein, limiting the precursor available to generate plasma kallikrein and providing sustained reduction in attack frequency through a gene-silencing mechanism used for long-term prophylaxis.
E) Donidalorsen is an oral bradykinin B1 receptor antagonist developed for chronic pain management in diabetic peripheral neuropathy that was subsequently found to reduce HAE attack severity as an off-label secondary indication when used in patients who have both conditions concurrently.
ANSWER: D
Rationale:
Donidalorsen is an RNA-targeted antisense oligonucleotide that binds prekallikrein messenger RNA in hepatocytes and triggers its degradation (via RNase H1), selectively reducing hepatic production of plasma prekallikrein — the zymogen precursor of plasma kallikrein. By lowering the available prekallikrein pool, it limits kallikrein-mediated cleavage of high-molecular-weight kininogen and the resulting bradykinin generation, reducing the frequency of HAE attacks. It is administered subcutaneously at extended intervals (approximately every 4 to 8 weeks) and is used for long-term prophylaxis rather than acute attack treatment. Its significance is as a first-in-class RNA-targeted (gene-silencing) prophylactic option, distinct from the enzyme inhibitors, receptor antagonists, and protein-replacement products used elsewhere in HAE.
Option A: Option A is incorrect because it describes an oral small-molecule plasma kallikrein inhibitor for on-demand (acute attack) treatment — the profile of a separate agent (sebetralstat), not donidalorsen; donidalorsen is not an oral small molecule, does not directly inhibit kallikrein enzyme activity, and is a prophylactic agent rather than an acute treatment.
Option B: Option B is incorrect because a subcutaneous factor XIIa-targeted monoclonal antibody for once-monthly prophylaxis describes garadacimab, not donidalorsen; donidalorsen acts upstream by reducing prekallikrein synthesis, not by binding factor XIIa, and it is an antisense oligonucleotide rather than a monoclonal antibody.
Option C: Option C is incorrect because extended-half-life recombinant C1 inhibitor concentrates are a separate category of protein-replacement product; donidalorsen is not a C1 inhibitor or any protein-replacement biologic — it is a nucleic-acid (antisense oligonucleotide) therapeutic.
Option E: Option E is incorrect because donidalorsen was developed as a primary HAE prophylactic agent, not as a pain drug repurposed for HAE; it is not a bradykinin B1 receptor antagonist, and B1 receptor antagonism for diabetic peripheral neuropathy is an unrelated research program that has not produced an approved drug.
22. A resident learning about emerging HAE pipeline agents reads about garadacimab, an investigational monoclonal antibody in phase III development for HAE prophylaxis. Which of the following correctly identifies garadacimab's pharmacological target and explains how it differs mechanistically from lanadelumab?
A) Garadacimab is a monoclonal antibody that targets plasma kallikrein — the same enzyme inhibited by lanadelumab — but with greater binding affinity; because both agents target kallikrein, garadacimab offers a dosing frequency advantage (once monthly versus every 2 weeks for lanadelumab) without introducing a new mechanism of action.
B) Garadacimab is a monoclonal antibody targeting the bradykinin B2 receptor formulated as a long-acting depot injection that provides prophylactic receptor blockade for 4 to 6 weeks per dose, preventing bradykinin from acting at its receptor throughout the dosing interval without affecting bradykinin generation.
C) Garadacimab is a monoclonal antibody that targets activated factor XII (factor XIIa) — the contact system protein that initiates the kallikrein-kinin cascade — blocking the cascade at a step upstream of kallikrein, unlike lanadelumab, which blocks kallikrein one step downstream; both approaches prevent bradykinin generation but at different points in the same activation sequence.
D) Garadacimab is a bispecific monoclonal antibody targeting both factor XIIa and plasma kallikrein simultaneously, providing more complete contact system inhibition than either single-target agent alone and enabling monthly dosing in patients who have breakthrough attacks on lanadelumab or C1-INH prophylaxis.
E) Garadacimab is a monoclonal antibody that targets HMWK (high-molecular-weight kininogen) — the bradykinin precursor protein — preventing it from being cleaved by kallikrein; this mechanism is distinct from both lanadelumab (which inhibits kallikrein) and icatibant (which blocks the B2 receptor) by attacking the substrate rather than the enzyme or receptor.
ANSWER: C
Rationale:
Garadacimab is an anti-factor XIIa monoclonal antibody that blocks the contact activation cascade at its initiating trigger — factor XII activation. Factor XIIa is the activated form of factor XII (Hageman factor), which initiates the cascade when it contacts negatively charged surfaces (such as those produced by bacterial endotoxin, negatively charged macromolecules, or tissue damage), leading sequentially to prekallikrein activation → plasma kallikrein → cleavage of HMWK → bradykinin generation. By blocking factor XIIa, garadacimab intercepts the cascade one step upstream of where lanadelumab acts: lanadelumab inhibits plasma kallikrein (the enzyme that directly generates bradykinin from HMWK), while garadacimab prevents kallikrein from being activated in the first place by blocking the factor that converts prekallikrein to kallikrein. Phase III data show robust attack rate reduction with monthly subcutaneous dosing.
Option A: Option A is incorrect because garadacimab targets factor XIIa, not plasma kallikrein; describing both garadacimab and lanadelumab as kallikrein-targeting agents misidentifies the mechanistic distinction that defines garadacimab's investigational interest — its value lies precisely in acting upstream of kallikrein at factor XIIa.
Option B: Option B is incorrect because garadacimab does not target the bradykinin B2 receptor; a long-acting depot B2 receptor antagonist does not describe any currently approved or late-stage investigational HAE drug; garadacimab acts on the enzyme side (factor XIIa), not the receptor side of bradykinin pharmacology.
Option D: Option D is incorrect because garadacimab is a monospecific antibody targeting factor XIIa only, not a bispecific antibody targeting both factor XIIa and kallikrein; combining two enzyme targets in a single bispecific antibody for HAE is not the approved design of garadacimab.
Option E: Option E is incorrect because garadacimab does not target HMWK; HMWK-directed approaches are theoretically conceivable but do not describe garadacimab; garadacimab acts upstream of HMWK cleavage by blocking factor XIIa — the trigger that activates the kallikrein responsible for HMWK cleavage.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.